Xemed announced today that its fourth-generation xenon polarizer “Hawking”, which is the prototype for its commercial quality MagniXene™ production platform XeBox-E10, was deployed to the University of Virginia Medical School for collaborative work within the Center for In-Vivo Hyperpolarized Gas MR Imaging. A full team of Xemed scientists will join the Virginia team for the first imaging sessions, scheduled during the next week. Two months of collaborative studies are currently planned, including studies coordinated on-site by G. Wilson Miller, PhD which are funded by the National Heart, Lung, and Blood Institute to validate regional measurements of alveolar oxygen, and studies coordinated on-site by Talissa A. Altes MD which are funded by a pharmaceutical company to compare imaging biomarkers of cystic fibrosis severity.
Xemed announces first clinical deployment of its fourth-generation xenon polarizer
ABOUT XEMED—We are a product-focused diagnostic drug company with broad expertise and IP in the field of hyperpolarized gases, partnering with clinical researchers and the pharmaceutical industry to advance pulmonary functional MRI through regulatory approval towards worldwide commercial availability.
At Xemed, our mission is to develop inhaled diagnostic agents that are capable of improving the standard of care of respiratory diseases. We will accomplish this by establishing hyperpolarized gas as a scientifically robust, clinically validated, FDA approved, and publically available diagnostic agent for magnetic resonance imaging of lung functional microstructure. We work to demonstrate effectiveness in two fields: 1) guiding clinical management of respiratory diseases, and 2) as a drug development tool to evaluate of the safety and efficacy of new therapies